Isotechnika Pharma Inc IPHAF

RE: POSITIVE NEWS? JUST MORE PR. BS. , DEFLECT

[isatheone]

"The Nicams "WORK SYNERGISTICALLY" with inteferon,  NOT ON ITS" OWN!!!! "

NOT TRUE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

FROM THE PRESS RELEASE: Results demonstrate that the NICAMs are highly active (low nanomolar potency) against HCV genotypes, 1 and 2, which represent approximately 85% of the HCV infections globally. Direct-acting HCV anti-viral drugs currently on the market are approved only for genotype 1 infections. Testing ALSO [NOT ONLY LIKE YOU CLAIM) revealed that the NICAM compounds acted synergistically with alpha interferon, the current standard of care treatment, in reducing viral activity. The presence of synergistic activity means that significantly lower drug doses may be possible, thereby limiting the adverse events associated with interferon treatment. These findings support the view that NICAMs will broaden the therapeutic treatment window by complementing other classes of HCV drugs in development.